Therapeutic Management and Use of Resources and Costs of Spinal Muscular Atrophy in Spain

NCT06632730 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 69

Last updated 2024-10-09

No results posted yet for this study

Summary

An observational, retrospective, cross-sectional, multicenter study. Real-world data were obtained from medical records of Spanish public hospitals (9 hospitals).

Conditions

  • Spinal Muscular Atrophy Type I
  • Spinal Muscular Atrophy Type II

Sponsors & Collaborators

Principal Investigators

  • Novartis Pharmaceuticals · Novartis Pharmaceuticals

Eligibility

Max Age
14 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-07-05
Primary Completion
2023-11-20
Completion
2023-11-20

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06632730 on ClinicalTrials.gov